Gastroesophageal adenocarcinoma

This study tests whether a new drug called zanidatamab, combined with chemotherapy and sometimes another drug (tislelizumab), works better than the current standard treatment for advanced HER2-positive stomach and esophageal cancers. About 920 adults whose cancer has spread or ca…

This phase 2 trial is testing whether adding radiation therapy to the immunotherapy drug nivolumab can help people with advanced gastroesophageal cancer live longer without their disease getting worse. All 80 participants first receive a short course of chemotherapy (FOLFOX) plus…

This phase 2 trial tests different chemotherapy combinations for people with advanced stomach or esophageal cancer that has spread or cannot be removed. The study compares a new liposomal form of irinotecan plus other drugs against standard treatments to see which works best at s…

This trial tests whether combining an immunotherapy drug (tislelizumab) with standard chemotherapy and heated chemotherapy delivered directly into the abdomen can shrink tumors and improve survival in people with stomach cancer that has spread to the lining of the abdomen. The st…

This early-phase trial is testing whether combining two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and lenvatinib (which blocks enzymes that help tumors grow)—can shrink tumors in people with advanced stomach or gastroesophageal cancer that …

This phase 3 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy after stomach cancer surgery can help prevent the cancer from coming back. About 878 patients who had their stomach cancer completely removed will receive either toripalimab plus c…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This study tests whether combining the targeted drug trastuzumab-deruxtecan with other treatments before surgery is safe and feasible for people with HER2-positive stomach or esophagus cancer that has not spread. About 36 adults will receive the drug combinations before their pla…

This pilot trial tests whether using a patient's genetic profile to determine the dose of irinotecan (a chemotherapy drug) can improve outcomes for people with advanced stomach or esophageal cancer. The study combines chemotherapy before and after surgery, with the goal of increa…

This early-stage study tests the safety of tucatinib in about 25 Chinese patients with advanced HER2+ breast, stomach, or colorectal cancer that has worsened after standard treatments. Researchers will monitor side effects and how the drug moves through the body. The goal is to s…

This study tests an experimental drug called LM-302 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after at least two prior therapies. The trial includes 387 adults whose tumors have a specific protein (CLDN1…

This study tests a drug called bemarituzumab combined with different chemotherapies in 126 people with advanced stomach or gastroesophageal junction cancer that has a specific protein (FGFR2b). Participants have already tried at least one prior chemotherapy. The goal is to see if…

This early-phase study tests an experimental drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can sh…

This observational study collects blood and tumor tissue samples from people with gastroesophageal cancer to study genetic changes that may cause resistance to immunotherapy. It does not involve any treatment or experimental drugs. The goal is to identify new targets for future i…